JP6964298B2 - ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト - Google Patents
ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト Download PDFInfo
- Publication number
- JP6964298B2 JP6964298B2 JP2018568338A JP2018568338A JP6964298B2 JP 6964298 B2 JP6964298 B2 JP 6964298B2 JP 2018568338 A JP2018568338 A JP 2018568338A JP 2018568338 A JP2018568338 A JP 2018568338A JP 6964298 B2 JP6964298 B2 JP 6964298B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- pyrrolidine
- trans
- bis
- conhch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 O=C([C@@](C*C1)[C@@]1C(N[C@](C1)[C@]1c1ccccc1)=O)N[C@@](C1)[C@]1c1ccccc1 Chemical compound O=C([C@@](C*C1)[C@@]1C(N[C@](C1)[C@]1c1ccccc1)=O)N[C@@](C1)[C@]1c1ccccc1 0.000 description 7
- GGMJHHPITDKZJS-HWRYWDHUSA-N COC(c(cc1)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O Chemical compound COC(c(cc1)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O GGMJHHPITDKZJS-HWRYWDHUSA-N 0.000 description 2
- HOHJQBXDDLVXLX-QALHXSLCSA-N C=NC([C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(N)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(N)=O)=O Chemical compound C=NC([C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(N)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(N)=O)=O HOHJQBXDDLVXLX-QALHXSLCSA-N 0.000 description 1
- POKLWXICTNJANQ-HFJPHANOSA-N CC(CCN(CCC(N[C@@H](C1)[C@H]1c1ccccc1)=O)C(c(cc1)ccc1C(N(CCC(N[C@@H](C1)[C@H]1c1ccccc1)=O)CCC(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O)(N[C@@H](C1)[C@H]1c1ccccc1)O Chemical compound CC(CCN(CCC(N[C@@H](C1)[C@H]1c1ccccc1)=O)C(c(cc1)ccc1C(N(CCC(N[C@@H](C1)[C@H]1c1ccccc1)=O)CCC(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O)(N[C@@H](C1)[C@H]1c1ccccc1)O POKLWXICTNJANQ-HFJPHANOSA-N 0.000 description 1
- MNBATXISJUVTDS-ZJXHUGRPSA-N CCCCCCCCCCCCCCCCNC([C@H](CC1)CN1C(c(cc1)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCCNC([C@H](CC1)CN1C(c(cc1)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O)=O MNBATXISJUVTDS-ZJXHUGRPSA-N 0.000 description 1
- LLGXSAHAOVUTIR-VGUKHLMCSA-N CCCCCCCCCCCCCCNC([C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(NCCCCCCCCCCCCCC)=O)C[C@H]2C(NCCCCCCCCCCCCCC)=O)=O)=O)[C@@H]1C(NCCCCCCCCCCCCCC)=O)=O Chemical compound CCCCCCCCCCCCCCNC([C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(NCCCCCCCCCCCCCC)=O)C[C@H]2C(NCCCCCCCCCCCCCC)=O)=O)=O)[C@@H]1C(NCCCCCCCCCCCCCC)=O)=O LLGXSAHAOVUTIR-VGUKHLMCSA-N 0.000 description 1
- NFHWVVVFJGSKJG-UYMKNZQYSA-N COc(cc(cc1)C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)c1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O Chemical compound COc(cc(cc1)C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)c1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O NFHWVVVFJGSKJG-UYMKNZQYSA-N 0.000 description 1
- VZAJTFCSQYJAOI-FCTGFMJPSA-N C[C@@H](C1)[C@H]1NC([C@H](CNC1)[C@@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O Chemical compound C[C@@H](C1)[C@H]1NC([C@H](CNC1)[C@@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O VZAJTFCSQYJAOI-FCTGFMJPSA-N 0.000 description 1
- OHSOXYBIKPSCSK-UHFFFAOYSA-N Cc1ccc(C2CC2)cc1 Chemical compound Cc1ccc(C2CC2)cc1 OHSOXYBIKPSCSK-UHFFFAOYSA-N 0.000 description 1
- PWLLOLBVZUSIPU-AXYJRABVSA-N Nc1ccc(CCNC([C@@H](CN(C2)C(c(cc3)ccc3C(N(C[C@@H]3C(NCCc(cc4)ccc4N)=O)C[C@@H]3C(NCCc(cc3)ccc3N)=O)=O)=O)[C@H]2C(NCCc(cc2)ccc2N)=O)=O)cc1 Chemical compound Nc1ccc(CCNC([C@@H](CN(C2)C(c(cc3)ccc3C(N(C[C@@H]3C(NCCc(cc4)ccc4N)=O)C[C@@H]3C(NCCc(cc3)ccc3N)=O)=O)=O)[C@H]2C(NCCc(cc2)ccc2N)=O)=O)cc1 PWLLOLBVZUSIPU-AXYJRABVSA-N 0.000 description 1
- GHTLRZPFBYFYIX-YIVJUVAHSA-N O=C(Cc1cccc(CC(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(NC(C2)[C@H]2c2ccccc2)=O)=O)c1)N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O Chemical compound O=C(Cc1cccc(CC(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(NC(C2)[C@H]2c2ccccc2)=O)=O)c1)N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O GHTLRZPFBYFYIX-YIVJUVAHSA-N 0.000 description 1
- JMKSTIGMMGNBNT-AXYJRABVSA-N O=C([C@@H](CN(C1)C(c(cc2)ccc2C(N(C[C@@H]2C(NCCc(cc3)ccc3F)=O)C[C@@H]2C(NCCc(cc2)ccc2F)=O)=O)=O)[C@H]1C(NCCc(cc1)ccc1F)=O)NCCc1ccccc1 Chemical compound O=C([C@@H](CN(C1)C(c(cc2)ccc2C(N(C[C@@H]2C(NCCc(cc3)ccc3F)=O)C[C@@H]2C(NCCc(cc2)ccc2F)=O)=O)=O)[C@H]1C(NCCc(cc1)ccc1F)=O)NCCc1ccccc1 JMKSTIGMMGNBNT-AXYJRABVSA-N 0.000 description 1
- YXCVPMJAJXNYJA-YYHFWCTESA-N O=C([C@@H](CN(C1)C(c(cc2)ccc2C(N(C[C@@H]2C(NCCc3cc4ccccc4cc3)=O)C[C@@H]2C(NCCc2cc3ccccc3cc2)=O)=O)=O)[C@H]1C(NCCc1cc(cccc2)c2cc1)=O)NCCc1cc(cccc2)c2cc1 Chemical compound O=C([C@@H](CN(C1)C(c(cc2)ccc2C(N(C[C@@H]2C(NCCc3cc4ccccc4cc3)=O)C[C@@H]2C(NCCc2cc3ccccc3cc2)=O)=O)=O)[C@H]1C(NCCc1cc(cccc2)c2cc1)=O)NCCc1cc(cccc2)c2cc1 YXCVPMJAJXNYJA-YYHFWCTESA-N 0.000 description 1
- NJHIKCKHBGSNMX-ABSGTHFKSA-N O=C([C@H](CN(C1)C(c(c(Cl)c2)cc(Cl)c2C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)N[C@@H](C1)[C@H]1c1ccccc1 Chemical compound O=C([C@H](CN(C1)C(c(c(Cl)c2)cc(Cl)c2C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)N[C@@H](C1)[C@H]1c1ccccc1 NJHIKCKHBGSNMX-ABSGTHFKSA-N 0.000 description 1
- LUWUKRPIBRNBIP-AXRJLGSNSA-N O=C([C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(NCCc3ccccc3)=O)C[C@H]2C(NCCc2ccccc2)=O)=O)=O)[C@@H]1C(NCCc1ccccc1)=O)NCCc1ccccc1 Chemical compound O=C([C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(NCCc3ccccc3)=O)C[C@H]2C(NCCc2ccccc2)=O)=O)=O)[C@@H]1C(NCCc1ccccc1)=O)NCCc1ccccc1 LUWUKRPIBRNBIP-AXRJLGSNSA-N 0.000 description 1
- RWIKJXVMMOLLSJ-GJLCVQKQSA-N O=C([C@H](CN(C1)C(c(cc2)ccc2C(N2CCCC2)=O)=O)[C@@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)N[C@@H](C1)[C@H]1c1ccccc1 Chemical compound O=C([C@H](CN(C1)C(c(cc2)ccc2C(N2CCCC2)=O)=O)[C@@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)N[C@@H](C1)[C@H]1c1ccccc1 RWIKJXVMMOLLSJ-GJLCVQKQSA-N 0.000 description 1
- QJINWJMYHATXTK-VSGBNLITSA-N O=C([C@H](CNC1)[C@@H]1C(NCCc1ccc(cccc2)c2c1)=O)NCCc1cc2ccccc2cc1 Chemical compound O=C([C@H](CNC1)[C@@H]1C(NCCc1ccc(cccc2)c2c1)=O)NCCc1cc2ccccc2cc1 QJINWJMYHATXTK-VSGBNLITSA-N 0.000 description 1
- LERNJAOHJUCDBL-QXYCXYOSSA-N OC(CNC(COc1cc(C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(NC(C1)[C@H]1c1ccccc1)=O)=O)=O)=O Chemical compound OC(CNC(COc1cc(C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(NC(C1)[C@H]1c1ccccc1)=O)=O)=O)=O LERNJAOHJUCDBL-QXYCXYOSSA-N 0.000 description 1
- FJLJAIDKKADIGJ-NIVXRMQLSA-N OC(c(cc1)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O Chemical compound OC(c(cc1)ccc1C(N(C[C@H]1C(N[C@@H](C2)[C@H]2c2ccccc2)=O)C[C@H]1C(N[C@@H](C1)[C@H]1c1ccccc1)=O)=O)=O FJLJAIDKKADIGJ-NIVXRMQLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356314P | 2016-06-29 | 2016-06-29 | |
| US62/356,314 | 2016-06-29 | ||
| PCT/US2017/040028 WO2018005812A1 (en) | 2016-06-29 | 2017-06-29 | Diprovocims: a new and potent class of tlr agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519574A JP2019519574A (ja) | 2019-07-11 |
| JP2019519574A5 JP2019519574A5 (https=) | 2020-08-06 |
| JP6964298B2 true JP6964298B2 (ja) | 2021-11-10 |
Family
ID=60787607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568338A Active JP6964298B2 (ja) | 2016-06-29 | 2017-06-29 | ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11040959B2 (https=) |
| EP (1) | EP3445758B1 (https=) |
| JP (1) | JP6964298B2 (https=) |
| KR (1) | KR102522730B1 (https=) |
| CN (1) | CN109641878B (https=) |
| AU (1) | AU2017290238B2 (https=) |
| BR (1) | BR112018077397A2 (https=) |
| CA (1) | CA3026178C (https=) |
| IL (1) | IL263388B (https=) |
| WO (1) | WO2018005812A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164445A (zh) * | 2018-08-02 | 2021-07-23 | 得克萨斯系统大学评议会 | Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病 |
| JP2023527792A (ja) | 2020-05-27 | 2023-06-30 | アキシャル セラピューティクス，インク． | Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用 |
| US20250367166A1 (en) * | 2022-04-29 | 2025-12-04 | The Scripps Research Institute | Next generation diprovocims that activate the innate and adaptive immune response |
| US20260091126A1 (en) * | 2022-09-20 | 2026-04-02 | The Curators Of The University Of Missouri | Amino acid-modified lipids for rna delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1418905T3 (da) | 2001-08-08 | 2007-09-10 | Pentraxin Therapeutics Ltd | Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma |
| WO2005016235A2 (en) * | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
| PE20071079A1 (es) | 2005-11-15 | 2007-12-16 | Cytokinetics Inc | Compuestos de piperidina como inhibidores de la proliferacion celular |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| EP2958889B1 (en) | 2013-02-25 | 2017-03-22 | The Scripps Research Institute | Neoseptins: small molecule adjuvants |
| US9918959B2 (en) | 2014-08-06 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | TLR-independent small molecule adjuvants |
-
2017
- 2017-06-29 KR KR1020197002820A patent/KR102522730B1/ko active Active
- 2017-06-29 BR BR112018077397A patent/BR112018077397A2/pt unknown
- 2017-06-29 EP EP17821259.3A patent/EP3445758B1/en active Active
- 2017-06-29 CN CN201780040830.9A patent/CN109641878B/zh active Active
- 2017-06-29 CA CA3026178A patent/CA3026178C/en active Active
- 2017-06-29 WO PCT/US2017/040028 patent/WO2018005812A1/en not_active Ceased
- 2017-06-29 JP JP2018568338A patent/JP6964298B2/ja active Active
- 2017-06-29 US US16/303,043 patent/US11040959B2/en active Active
- 2017-06-29 AU AU2017290238A patent/AU2017290238B2/en active Active
-
2018
- 2018-11-29 IL IL263388A patent/IL263388B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641878B (zh) | 2021-09-14 |
| CA3026178C (en) | 2024-05-21 |
| WO2018005812A1 (en) | 2018-01-04 |
| KR20190014133A (ko) | 2019-02-11 |
| CA3026178A1 (en) | 2018-01-04 |
| IL263388A (en) | 2018-12-31 |
| EP3445758A1 (en) | 2019-02-27 |
| US11040959B2 (en) | 2021-06-22 |
| AU2017290238B2 (en) | 2021-02-18 |
| EP3445758A4 (en) | 2019-09-25 |
| BR112018077397A2 (pt) | 2019-10-01 |
| KR102522730B1 (ko) | 2023-04-19 |
| AU2017290238A1 (en) | 2018-12-13 |
| CN109641878A (zh) | 2019-04-16 |
| JP2019519574A (ja) | 2019-07-11 |
| IL263388B (en) | 2021-02-28 |
| EP3445758B1 (en) | 2020-11-04 |
| US20200207742A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7829523B2 (ja) | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 | |
| JP6964298B2 (ja) | ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト | |
| CN109415387B (zh) | 精氨酸酶抑制剂及其治疗应用 | |
| CN108794422B (zh) | 作为pd-l1抑制剂的杂环类化合物 | |
| CN108697715A (zh) | 包含帽依赖性核酸内切酶抑制剂及抗流感药的组合的流感治疗用药物 | |
| US20030096841A1 (en) | Isoindole-imide compounds, compositions, and uses thereof | |
| KR20030078064A (ko) | 이소인돌-이미드 화합물, 조성물 및 이의 용도 | |
| JP6805172B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| CN115867319A (zh) | 用于局部递送治疗剂的药物递送系统以及其用途 | |
| JP6643484B2 (ja) | ７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３．２．１］オクタン−２−カルボキサミド含有化合物および細菌感染症の治療におけるそれらの使用 | |
| TW201217332A (en) | Caspase inhibitors and uses thereof | |
| TWI813106B (zh) | 雄性激素受體結合分子及其用途 | |
| US20220213099A1 (en) | Prodrug compounds | |
| TW442469B (en) | Fibrinogen receptor antagonists having substituted β-amino acid residues and pharmaceutical compositions comprising the same | |
| KR20260018876A (ko) | 항-hiv 화합물 | |
| JPWO2006090853A1 (ja) | 含窒素複素環化合物およびその医薬用途 | |
| RU2860767C2 (ru) | Ингибиторы nek7 | |
| AU2009279098B2 (en) | Process for the preparation of nicotine-based haptens | |
| JPH11199561A (ja) | シス置換アミノシクロプロパン化合物 | |
| JP3874455B2 (ja) | フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤 | |
| HK40107352B (zh) | 用於局部递送治疗剂的药物递送系统以及其用途 | |
| HK40107352A (zh) | 用於局部递送治疗剂的药物递送系统以及其用途 | |
| CA3167691A1 (en) | Fentanyl haptens for the preparation of a fentanyl vaccine | |
| WO2003076402A1 (fr) | Analgesique | |
| JPH1081682A (ja) | シス置換アミノシクロプロパン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200626 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200626 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210715 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210908 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211008 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6964298 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |